Background {#Sec1}
==========

Ovarian cancer is the leading cause of death from gynecologic malignancy worldwide \[[@CR1]\]. In Korea, the incidence and mortality rates of ovarian cancer are steadily increasing \[[@CR2]--[@CR4]\]. The standard treatment for advanced-stage ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy \[[@CR5], [@CR6]\]. Despite an initial response to standard treatment, the overall 5-year survival rate of advanced-stage ovarian cancer is approximately 30% \[[@CR7]\]. However, there has been no significant change in the accepted approach to treatment during the last two decades, which has hampered improvements in long-term survival \[[@CR8]\].

In part, this is due to epithelial ovarian cancer being considered as a heterogeneous disease across different histologic subtypes, including high-grade serous carcinoma (HGSC), clear cell carcinoma, endometrioid, mucinous carcinoma, and low-grade serous carcinoma (LGSC) \[[@CR9]\]. Since 1999, the incidence of clear cell carcinoma has increased markedly across all age groups in Korea \[[@CR10]\]. Furthermore, histologic subtypes other than HGSC (non-HGSC) are known to have poorer clinical outcomes in response to conventional chemotherapy due to resistance and reduced sensitivity of these subtypes to chemotherapy \[[@CR11]--[@CR15]\]. Previous clinical data have indicated that survival outcome correlates with the histological subtype \[[@CR11]\]. However, all ovarian cancers continue to be treated with the same therapeutic strategy regardless of subtype.

Some previous studies showed that patients with non-HGSC had poorer survival than those with HGSC in primary debulking surgery (PDS) \[[@CR14]--[@CR18]\]. There are several randomized studies showing that neoadjuvant chemotherapy (NAC) is non-inferior to PDS for patients with advanced epithelial ovarian cancer \[[@CR19]--[@CR21]\]. However, NAC has primarily been evaluated by studies focusing on HGSC \[[@CR22]\] and currently there are no published studies on NAC outcomes in patients with non-HGSC. Furthermore, although non-HGSC is considered a different disease entity than HGSC, it is not yet known whether the selection criteria for NAC and the treatment regimen of NAC should be the same for patients with non-HGSC as those for patients with HGSC.

Therefore, we conducted a multicenter retrospective cohort study to evaluate the clinical, surgical and survival outcomes of non-HGSC patients with advanced-stage ovarian cancer after NAC.

Methods {#Sec2}
=======

From 2002 to 2017, 154 patients who had undergone NAC for advanced stage non-HGSC were enrolled from 17 institutions affiliated with the Korean Gynecologic Oncology Group (KGOG). We showed the number of enrolled patients from each institution in Additional file [1](#MOESM1){ref-type="media"}: Table S1. We performed a retrospective cohort study and data were collected from medical records. This study was approved by the institutional review boards of the participating centers in accordance with the Declaration of Helsinki and the International Conference of Harmonization Good Clinical Practice Guidelines.

Inclusion criteria for patients were as follows: (1) diagnosed and histologically confirmed with non-HGSC subtype of epithelial ovarian cancer; (2) diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV; (3) received at least 1 cycle of NAC with or without interval debulking surgery (IDS); and (4) had available medical records and follow-up data. All cases diagnosed as non-HGSC subtype by cytologic evaluation of ascites/pleural effusion, image-guided aspiration biopsy, diagnostic laparoscopic/laparotomy biopsy, or after IDS were included. The exclusion criteria were as follows: (1) non-epithelial ovarian cancer; (2) HGSC; (3) FIGO stage I or II; (4) borderline epithelial ovarian cancer; and (5) PDS as primary therapy.

Reasons for the use of NAC varied due to the long-term, multicenter, retrospective nature of this analysis. Therefore, reasons for the use of NAC were collected from each patient.

Clinical staging of epithelial ovarian cancer was performed according to the FIGO system (2014) following the use of computed tomography (CT) and positron emission tomography (PET)/CT for preoperative imaging workup. Response to chemotherapy was evaluated after the third cycle of NAC using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria \[[@CR23]\].

All patients received NAC as primary therapy with various regimens in accordance with institutional policy. Standard surgical procedure consisted of total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, or retroperitoneal lymphadenectomy. Radical surgeries were defined as bowel resection, diaphragm/peritoneal surface stripping, splenectomy, liver resection, partial gastrectomy, or partial cystectomy/ureteroneocystostomy. Postoperative complications were graded according to the Memorial Sloan-Kettering Cancer Center's (MSKCC) surgical secondary events grading system \[[@CR24]\]. We defined the major surgical complications as MSKCC grade ≥ 3. After surgery, patients underwent various cycles and regimens of postoperative adjuvant chemotherapy (POAC). Histologic subtypes were confirmed according to the criteria of the World Health Organization classification; however, there was no central review of all microscopic slides. After the completion of primary treatment, all patients underwent institutional routine clinical follow-up, consisting of imaging studies and blood tests. During follow-up, clinical assessment including pelvic examination, serum CA-125 level were every 2--3 months, and imaging studies such as contrast-enhanced CT scan was performed every 6 months.

Statistical analysis {#Sec3}
--------------------

Continuous variables were described as median and range (minimum and maximum value), while categorical data were described by frequencies and percentages (%). Progression-free survival (PFS) was defined as the time from the date of first NAC to the date of first recurrence or the date of last follow-up. Recurrence or progression was diagnosed by radiologic finding, but not by elevated CA-125 level alone. Overall survival (OS) was defined as the time from the date of first NAC to the date of death or the date of last follow-up. At each institution, survival data were extracted from their own cancer registry linked with death certificate. Kaplan-Meier survival curves were calculated using the log-rank test. Univariate and multivariate analyses were evaluated using a Cox proportional hazard model, and prognostic factors affecting PFS and OS were evaluated. A *p*-value \< 0.05 was considered to indicate statistical significance. Data were analyzed with IBM SPSS, version 23 for Windows (IBM Corp, Armonk, NY, USA).

Results {#Sec4}
=======

Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Of the enrolled 154 patients, 20 patients (13.0%) were diagnosed with mucinous adenocarcinoma; 31 (20.1%) with endometrioid adenocarcinoma; 28 (18.2%) with clear cell carcinoma; 29 (18.8%) with LGSC; and 12 (7.8%) with carcinosarcoma. Three patients did not undergo IDS and 8 patients did not receive POAC. The median number of NAC cycles, POAC cycles, and total chemotherapy cycles were 3 (range: 1--10), 6 (range: 0--22), and 9 (range: 2--28), respectively. Most of patients treated with a platinum-taxane combination of NAC (*n* = 152, 98.7%) or POAC (*n* = 129, 83.6%). Various methods of diagnosis were used before NAC: cytology of ascites in 59 cases (38.3%), diagnostic laparoscopy/laparotomy in 41 cases (26.6%), aspiration biopsy in 31 cases (20.1%), and cytology of pleural effusion in 14 cases (9.1%). However, histologic subtypes were confirmed before NAC in only 46 cases (*n* = 29.9%). Therefore, in some cases NAC was administered regardless of histologic subtype and according to criteria such as high tumor burden, older age, or poor Eastern Cooperative Oncology Group (ECOG). The reasons (multi-selectable) for NAC in patients with non-HGSC were high tumor burden (*n* = 106, 68.8%), old age/poor ECOG (*n* = 24, 15.6%), considered as HGSC before NAC (*n* = 8, 5.2%), being referred from another hospital after NAC (*n* = 5, 3.3%), and others such as policy of each institution (*n* = 30, 19.5%). NAC was obtained in 13 patients (8.4%) with both high tumor burden and old age/poor ECOG.Table 1Baseline characteristics of patients (*n* = 154)CharacteristicsN (%)Median age, years (range)54.0 (27.0--79.0)Median BMI at diagnosis, kg/m^2^ (range)22.5 (12.9--31.9)Median baseline CA-125 level, U/mL (range)808.0 (9.0--19,800.0)FIGO stage, n (%) III68 (44.2) IV86 (55.8)ASA score, n (%) 1--2122 (79.2) 3--421 (13.6) Unknown11 (7.2)Histologic subtype, n (%) Mucinous20 (13.0) Endometrioid31 (20.1) Clear cell28 (18.2) LGSC30 (19.5) Carcinosarcoma12 (7.8) Undifferentiated20 (13.0) Mixed5 (3.3) Anaplastic2 (1.3) Transitional3 (2.0) Squamous cell carcinoma2 (1.3) Ewing's sarcoma1 (0.6)Method of diagnosis, n (%) Ascites cytology59 (38.3) Pleural effusion cytology14 (9.1) Aspiration biopsy31 (20.1) Diagnostic laparoscopy24 (15.6) Diagnostic laparotomy4 (2.6) Laparoscopy in other hospital12 (7.8) Laparotomy in other hospital1 (0.6) Others5 (3.3) Not diagnosed before NAC4 (2.6)Confirm the histologic subtype before NAC, n (%) No108 (70.1) Yes46 (29.9)  HGSC5 (3.3)  Mucinous7 (4.6)  Endometrioid4 (2.6)  Clear cell8 (5.2)  LGSC9 (5.9)  Carcinosarcoma2 (1.3)  Others11 (7.1)Reasons for performing NAC^\*^, n (%) Old age / poor ECOG24 (15.6) High tumor burden106 (68.8) Considered as HGSC before NAC8 (5.2) Refer from other hospital after NAC5 (3.3) Others30 (19.5)NAC regimens, n (%) Paclitaxel + carboplatin137 (89.0) Paclitaxel + cisplatin6 (3.9) Docetaxel + carboplatin8 (5.2) Paclitaxel + carboplatin + bevacizumab1 (0.6) Others2 (1.3)POAC regimens, n (%) Paclitaxel + carboplatin114 (74.0) Paclitaxel + cisplatin5 (3.2) Docetaxel + carboplatin9 (5.8) Paclitaxel + carboplatin + bevacizumab1 (0.6) Others17 (11.0) Not done8 (5.2)*BMI* body mass index, *CA* 125 cancer antigen 125, *FIGO* Federation of Gynecology and Obstetrics, *ASA* American Society of Anesthesiologists, *NAC* neoadjuvant chemotherapy, *POAC* postoperative adjuvant chemotherapy, *HGSC* high-grade serous carcinoma, *LGSC* low-grade serous carcinoma, *ECOG* Eastern Cooperative Oncology Group^\*^Multi-selectable

The median follow-up duration was 20.3 months (range: 0.7--98.0 months), during which there were 107 recurrences and 56 deaths. Table [2](#Tab2){ref-type="table"} shows treatment outcomes after NAC and surgical outcomes. In response to NAC, decrease of CA-125 levels by more than 90% and normalization of CA-125 levels (\< 35 U/mL) from baseline to after the third cycle of NAC were observed in 61 (39.6%) and 49 (31.8) patients, respectively. After the third cycle of NAC, 100 (64.9%) patients showed complete remission or partial remission based on RECIST criteria. However, we could not know the response rate after the third cycle of NAC of 26 patients who received less than 3 cycles of NAC (*n* = 23) or did not perform any imaging workup after the third cycle of NAC (n = 3).Table 2Treatment outcomes after NAC/IDSCharacteristicsN (%)NAC response CA-125, n (%)  CA-125 after 3rd NAC \< 3549 (31.8)  CA-125 reduction rate ≥ 90%61 (39.6) Response rate after 3rd NAC, n (%)  CR2 (1.3)  PR98 (63.6)  SD21 (13.6)  PD7 (4.5)  Unknown26 (16.9)Surgical outcome Surgery extent, n (%)  Standard82 (53.3)  Radical69 (44.8)  Not surgery3 (1.9) Residual disease after IDS, n (%)  ≤1 cm103 (66.9)  \>1 cm25 (16.2)  Unknown26 (16.9) Lymphadenectomy, n (%)  (−)36 (23.4)  (+)115 (74.7)  Unknown3 (1.9) Lymph node metastasis, n (%)  No88 (57.2)  Yes63 (40.9)  Unknown3 (1.9) Peritoneal cytology, n (%)  Negative57 (37.0)  Positive63 (40.9) Not tested27 (17.5)  Unknown7 (4.6) Postoperative complications^\*^  0--2143 (92.9)  3--58 (5.2)  Unknown3 (1.9)*NAC* neoadjuvant chemotherapy, *IDS* interval debulking surgery, *HGSC* high-grade serous carcinoma, *CA* 125 cancer antigen 125, *CR* complete response, *PR* partial response, *SD* stable disease, *PD* progressive disease^\*^According to the Memorial Sloan-Kettering Cancer Center's surgical secondary events grading system

Regarding surgical outcomes, 103 (66.9%) patients underwent optimal debulking surgery (residual disease ≤1 cm). One hundred fifteen (74.7%) patients underwent lymphadenectomy and of these, 63 patients (40.9%) had lymph node metastasis. Sixty-three (40.9%) women had positive peritoneal cytology during IDS. Eight patients (5.2%) experienced major complications (MSKCC grade ≥ 3) related to surgery.

Survival analysis showed that the median PFS was 14.3 months and the median OS was 52.9 months (Fig. [1](#Fig1){ref-type="fig"}). The Kaplan-Meier curves stratified by histologic subtypes are shown in Fig. [2](#Fig2){ref-type="fig"}. PFS and OS differed significantly according to histologic subtypes (PFS, *p* = 0.002; OS, *p* \< 0.001). The median PFS by subtype was as follows: 6.9 months for mucinous adenocarcinoma, 17.4 months for endometrioid adenocarcinoma, 9.6 months for clear cell carcinoma, 16.6 months for LGSC, and 12.6 months for carcinosarcoma. The median OS by subtype was as follows: 12.2 months for mucinous adenocarcinoma, 35.7 months for clear cell carcinoma, 65.9 months for LGSC, and 31.0 months for carcinosarcoma, while the median OS for endometrioid adenocarcinoma was not reached. Overall, mucinous adenocarcinoma and clear cell carcinoma appeared to have the poorest survival prognosis. Multivariate Cox proportional hazards regression showed that American Society of Anesthesiologists score, residual tumor, and lymph node dissection all demonstrated an independent significant impact on PFS and OS. Furthermore, mucinous carcinoma was found to be a significantly negative predictor for both PFS (hazard ratio \[HR\]: 2.31, 95% confidence interval \[CI\]: 1.26--4.24, *p* = 0.007) and OS (HR: 3.24, 95% CI: 1.54--6.82, p = 0.002). Similarly, clear cell carcinoma also appeared to be a poor prognostic factor for both PFS (HR: 1.92, 95% CI: 1.12--3.29, *p* = 0.017) and OS (HR: 2.56, 95% CI: 1.21--5.30, *p* = 0.013) in patients who received NAC (Table [3](#Tab3){ref-type="table"}). Survival outcomes were significantly poorer in patients with mucinous (PFS, p \< 0.001; OS, p \< 0.001) or clear cell subtype (PFS, *p* = 0.001; OS, p = 0.002) compared to other subtypes (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1Kaplan-Meier survival curves for patients with non-HGSC. Progression-free survival (**a**). Overall survival (**b**). HGSC, high-grade serous carcinomaFig. 2Kaplan-Meier survival curves stratified by histologic subtype. Progression-free survival (**a**). Overall survival (**b**)Table 3Univariate and multivariate analyses for progression-free and overall survival using the Cox proportional hazard modelVariablesPFSOSUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR (95% CI) PHR (95% CI) PHR (95% CI) PHR (95% CI) PAge (years) \<551.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) ≥550.99 (0.67--1.44) 0.9391.33 (0.80--2.20) 0.2681.14 (0.67--1.92) 0.6341.51 (0.75--3.04) 0.245ASA 1--21.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) 3--42.29 (1.37--3.84) 0.0022.38 (1.26--4.51) 0.0083.12 (1.64--5.90) \< 0.0013.24 (1.54--6.82) 0.009Baseline CA-125 level (U/ml) ≤8001.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) \>8001.04 (0.71--1.53) 0.8261.14 (0.69--1.90) 0.6050.79 (0.47--1.34) 0.3820.93 (0.45--1.91) 0.838FIGO stage III1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) IV0.91 (0.62--1.33) 0.6290.74 (0.47--1.18) 0.2100.75 (0.44--1.26) 0.2770.62 (0.32--1.24) 0.177Histology Others1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) Mucinous2.64 (1.54--4.50) \< 0.0012.31 (1.26--4.24) 0.0074.69 (2.48--8.85) \< 0.0013.24 (1.54--6.82) 0.002 Clear cell2.10 (1.30--3.42) 0.0031.92 (1.12--3.29) 0.0172.62 (1.37--4.99) 0.0042.56 (1.21--5.30) 0.013Residual disease ≤1 cm1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) \>1 cm2.86 (1.75--4.66) \< 0.0012.40 (1.43--4.04) 0.0013.46 (1.89--6.33) \< 0.0012.43 (1.28--4.63) 0.007Surgery extent Standard1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) Radical0.94 (0.64--1.39) 0.7711.75 (1.02--2.99) 0.0420.98 (0.57--1.67) 0.9331.86 (0.97--3.56) 0.062LND No1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) Yes0.67 (0.17--2.76) 0.0040.33 (0.18--0.61) \< 0.0010.36 (0.09--1.49) 0.0020.32 (0.16--0.62) 0.001LN metastasis No1.00 (Reference)1.00 (Reference)1.00 (Reference)1.00 (Reference) Yes1.03 (0.25--4.26) 0.0742.89 (1.65--5.07) \< 0.0010.46 (0.11--1.97) 0.5531.78 (0.74--4.32) 0.201*PFS* progression-free survival, *OS* overall survival, *HR* hazard ratio, *CI* confidence interval, *ASA* American Society of Anesthesiologists, *CA*-125 cancer antigen 125, *FIGO* Federation of Gynecology and Obstetrics, *M/C* Mucinous/Clear, *LND* lymph node dissection, *LN* lymph nodeFig. 3Kaplan-Meier survival curves for patients with mucinous or clear cell carcinoma compared to other subtypes. Progression-free survival (**a**). Overall survival (**b**)

Discussion {#Sec5}
==========

In this multicenter retrospective cohort study, we found that non-HGSC had a poor response rate after the third cycle of NAC, low rate of optimal debulking surgery compared to other studies mainly focused on HGSC. In the CHORUS trial \[[@CR19]\], HGSC subtype rate was 71% and optimal debulking surgery rate was 73% and in Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasms \[[@CR21]\], HGSC subtype rate was 98.1%, optimal debulking surgery rate was 90.4%, and complete response/partial response rate according to RECIST was 90.9% in the NAC group.

The survival outcome in our study was not poor compared to the European Organization for Research and Treatment of Cancer (EORTC) 55,971 \[[@CR20]\] and in the CHORUS trial. The median PFS and OS for patients were 12 and 30 months, respectively, in the EORTC study and 12 and 24.1 months, respectively, in the CHORUS trial in the NAC group. However, we found that mucinous and clear cell subtypes in our study have poor survival from survival curves stratified by histologic subtypes and they could be independent prognostic factors for survival.

Ovarian cancer is typically considered as a single disease with a notably heterogeneous group of neoplasms. In particular, the pathogenesis of non-HGSCs has been shown to be unique for each histologic subtype, and the clinical understanding of the pathology and molecular biology of each subtype continues to improve. However, the current guidelines suggest the same treatment strategies for patients with ovarian cancer regardless of subtype. The findings of the present study show that different histologic subtypes have different prognoses, and the response to standard chemotherapy is generally poor in non-HGSC. Therefore, further studies and approaches that explore individualized treatment strategies for histologic subtypes are necessary.

In the NAC setting, maximal surgical effect is excluded and sensitivity and response to NAC has been a well-known prognostic factor for survival in advanced-stage ovarian cancer. While patients with HGSC tend to have good responses to taxane-platinum combination regimens, there are limited comparable data for patients with non-HGSC. Non-HGSC is not as frequent as HGSC, and thus it can be difficult to acquire prospective data. With data of the Korean Central Cancer registry, we previously showed that no improvement of survival outcomes was observed for patients with clear cell carcinoma and mucinous carcinoma during the past 20 years \[[@CR8]\]; additionally, it was not clear whether the selection criteria and regimen of NAC for patients with non-HGSC should be the same as those of patients with HGSC.

In the current study, confirmation of the histologic subtype before NAC was not common; indeed, the histologic subtypes of only 46 patients (29.9%) were identified before NAC. Thus, approximately 70% of the patients in our cohort received NAC without a histologic subtype evaluation. Histologic subtypes can be determined by diagnostic laparoscopy/laparotomy relatively easily, but cytologic evaluation of ascites and pleural effusions is more difficult. In our cohort, diagnostic laparoscopy/laparotomy was performed for just 41 patients (26.6%). An increased use of diagnostic laparoscopy could improve the rate of patients for whom histologic subtypes are identified prior to the decision to use treatment options such as PDS or NAC. Although we could not be sure for improved survival if patients without determining histologic subtypes underwent PDS instead of NAC, we could at least give a chance for clinical trials targeting specific molecular alterations associated with histologic subtypes. There is an unmet clinical need for novel therapeutic approaches tailored to patients with non-HGSC after NAC.

Recently, studies of specific histologic subtypes have been completed or are ongoing. For example, significantly higher levels of estrogen receptor (ER), progesterone receptor (PR), and E-cadherin have been shown to be expressed in LGSC compared to HGSC, \[[@CR25]\] and a consideration of these differences may lead to the development of different therapeutic strategies \[[@CR26]--[@CR29]\]. Based on retrospective studies \[[@CR29]\] showing the benefits of letrozole maintenance, MD Anderson group suggested a randomized phase III trial comparing letrozole and chemotherapy in LGSC. The MEK inhibitor (MILO) trial is a phase III study investigating the efficacy of MEK 162, a MEK inhibitor, compared to physician choice chemotherapy for recurrent or persistent LGSC. A phase III trial (Gynecologic Oncology Group (GOG)-241) compared the efficacy of chemotherapy regimens for mucinous carcinoma: capecitabine-oxaliplatin versus carboplatin-paclitaxel and with or without bevacizumab in mucinous subtype tumors was closed early for slow accrual, and neither of regimen clearly improved PFS or OS \[[@CR30], [@CR31]\]. Furthermore, in mucinous carcinoma, trastuzumab (Herceptin) may be effective for patients with HER2 overexpression \[[@CR32]\].

Efforts are ongoing worldwide to identify better strategies for treating clear cell carcinoma, as conventional chemotherapy is considered to be less effective for this particular subtype. One randomized phase III trial (Japanese Gynecologic Oncology Group (JGOG) 3017) compared an irinotecan-cisplatin regimen with a conventional paclitaxel-carboplatin regimen for clear cell carcinoma, but the irinotecan-cisplatin regimen did not show a significant survival benefit \[[@CR33]\]. Clear cell carcinoma frequently has both PIK3CA mutation (oncogene) and ARID1A mutation (tumor suppressor gene) \[[@CR34]\]. The GOG recently completed accrual of patients for a front-line, phase II study of temsirolimus, an mTOR inhibitor, used following paclitaxel/carboplatin as a first-line therapy in treating patients with newly diagnosed stage III/IV clear cell carcinoma (GOG-268). However, studies of each non-HGSC subtypes have been evaluated only in patients who underwent PDS. There are no studies to identify better strategies or develop of novel molecular target therapy for non-HGSC subtypes in patients who underwent NAC/IDS. Therefore, further studies are needed to suggested optimal therapies for non-HGSC subtypes.

This study has several limitations. First, a central pathology review was not performed. Central pathology review could establish uniform pathologic criteria for specimens from patients used in studies by reducing interobserver variability. Furthermore, this study includes quite a number of undifferentiated subtypes with unclear specific subtype. These data could be more accurately represented by a central pathology review. Second, because this study was performed as a multicenter retrospective analysis, no uniform selection criteria for NAC were established. Selection for NAC was determined by the patient's physical status, age, extent of the tumor burden, and policy of each institution, among other factors.

Despite these limitations, however, the current study is an important contribution to existing literature, as it is the first large retrospective analysis to evaluate the outcomes of non-HGSC patients after NAC in advanced-stage ovarian cancer.

Conclusions {#Sec6}
===========

In this study, significantly poor response rates and low rate of optimal debulking surgery were observed among patients with non-HGSC subtypes. Mucinous and clear cell carcinomas in particular could be negative prognostic factors for survival. Therefore, our findings suggest that different treatment strategies are essential and further studies with addition of targeted agents based on biomarker should be incorporated with priority to improve survival outcomes of patients with this disease subset.

Additional file
===============

 {#Sec7}

Additional file 1:**Table S1.** The list of enrolled patients from each institution (DOCX 24 kb)

CI

:   Confidence interval

CT

:   Computed tomography

ECOG

:   Eastern Cooperative Oncology Group

FIGO

:   Federation of Gynecology and Obstetrics

HGSC

:   High-grade serous carcinoma

HR

:   Hazard ratio

IDS

:   Interval debulking surgery

KGOG

:   Korean Gynecologic Oncology Group

LGSC

:   Low-grade serous carcinoma

MSKCC

:   Memorial Sloan-Kettering Cancer Center

NAC

:   Neoadjuvant chemotherapy

OS

:   Overall survival

PDS

:   Primary debulking surgery

PET

:   Positron emission tomography

PFS

:   Progression-free survival

POAC

:   Postoperative adjuvant chemotherapy

RECIST

:   Response Evaluation Criteria in Solid Tumors
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